CoCrystal Pharma, Inc. announced that progress with CC-42344 for the treatment of pandemic and seasonal influenza A from its Phase 1 study was presented on December 1, 2022 at the World Antiviral Congress 2022 underway in San Diego. In November 2022 Cocrystal reported that orally administered CC-42344 showed a favorable safety profile in both the single- and multiple-ascending dose portions of the Phase 1 study. The Company is currently awaiting pharmacokinetic results from this study and plans to report topline results later this year.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.729 USD | -1.19% | +6.09% | +0.41% |
05-01 | Cocrystal Pharma, Inc. Announces Completion of Enrollment of 78 Subjects | CI |
03-28 | Cocrystal Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.41% | 17.8M | |
+3.91% | 108B | |
+10.87% | 104B | |
+1.28% | 22.33B | |
-13.14% | 22.19B | |
-7.05% | 18.69B | |
-38.36% | 17.74B | |
-10.66% | 17.64B | |
+3.75% | 14.05B | |
+36.70% | 12.51B |
- Stock Market
- Equities
- COCP Stock
- News Cocrystal Pharma, Inc.
- CoCrystal Pharma, Inc. Highlights Progress with CC-42344 as Potential Oral Treatment for Pandemic and Seasonal Influenza A at World Antiviral Congress 2022